Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 5/2014

01-07-2014 | Astute Clinician Report

Secondary Hemophagocytic Lymphohistiocytosis (HLH) from a Presumed Brown Recluse Spider Bite

Authors: Christopher Dandoy, Michael Grimley

Published in: Journal of Clinical Immunology | Issue 5/2014

Login to get access

Abstract

Systemic loxoscelism is a rare complication after Loxosceles reclusa (brown recluse spider) envenomation. Loxosceles venom contains pro-inflammatory proteins, which have been shown to be elevated in patients with hemophagocytic lymph histiocytosis. We present a case of a 10-year-old male that developed presumed systemic loxoscelism, secondary hemophagocytic lymphohistiocytosis with hepatic dysfunction and renal failure. He was treated with dexamethasone and made a full recovery.
Literature
1.
Bronstein AC, Spyker DA, Cantilena LR, Rumack BH, Dart RC. 2011 annual report of the american association of poison control Centers’ national poison data system (NPDS): 29th annual report. Clin Toxicol. 2012;50:911–1164.CrossRef
2.
Rosen JL, Dumitru JK, Langley EW, Meade Olivier CA. Emergency department death from systemic loxoscelism. Ann Emerg Med. 2012;60:439–41.PubMedCrossRef
3.
Senff-Ribeiro A, Henrique Da Silva P, Chaim OM, et al. Biotechnological applications of brown spider (Loxosceles genus) venom toxins. Biotechnol Adv. 2008;26:210–8.PubMedCrossRef
4.
Isbister GK, Fan HW. Spider bite. The Lancet;378:2039–47.
5.
Hubbard JJ, James LP. Complications and outcomes of brown recluse spider bites in children. Clin Pediatr. 2011;50:252–8.CrossRef
6.
7.
Henter J-I, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.PubMedCrossRef
8.
Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100–3.PubMed
9.
Imashuku S. Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol. 2000;72:1–11.PubMed
10.
Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haem phagocytic syndrome. Br J Haematol. 2008;143:84–91.PubMedCrossRef
11.
Öst, Nilsson A, Henter. Autopsy findings in 27 children with haem phagocytic lymph histiocytosis. Histopathology 1998;32:310–6.
12.
Haddad E, Sulis M-L, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997;89:794–800.PubMed
13.
Tambourgi DV, Gonçalves-de-Andrade RM, van den Berg CW. Loxoscelism: from basic research to the proposal of new therapies. Toxicon. 2010;56:1113–9.PubMedCrossRef
14.
de Souza AL, Malaque CM, Sztajnbok J, Romano CC, Duarte AJ, Seguro AC. Loxosceles venom-induced cytokine activation, hemolysis, and acute kidney injury. Toxicon. 2008;51:151–6.PubMedCrossRef
15.
Tambourgi DV, Petricevich VL, Magnoli FC, Assaf SLMR, Jancar S, Dias Da Silva W. Endotoxemic-like shock induced by loxosceles spider venoms: pathological changes and putative cytokine mediators. Toxicon. 1998;36:391–403.PubMedCrossRef
16.
Lane L, McCoppin HH, Dyer J. Acute generalized exanthematous pustulosis and coombs-positive hemolytic anemia in a child following Loxosceles reclusa envenomation. Pediatr Dermatol. 2011;28:685–8.PubMedCrossRef
17.
Desai A, Miller MJ, Gomez HF, Warren JS. Loxosceles deserta spider venom induces NF-Κb-dependent chemokine production by endothelial cells. Clin Toxicol. 1999;37:447–56.CrossRef
Metadata
Title
Secondary Hemophagocytic Lymphohistiocytosis (HLH) from a Presumed Brown Recluse Spider Bite
Authors
Christopher Dandoy
Michael Grimley
Publication date
01-07-2014
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2014
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0036-1

Other articles of this Issue 5/2014

Journal of Clinical Immunology 5/2014 Go to the issue

Letter to Editor

A Novel Splice Site Mutation in the SERPING1 Gene Leads to Haploinsufficiency by Complete Degradation of the Mutant Allele mRNA in a Case of Familial Hereditary Angioedema

Original Research

Clinical and Genetic Characterization of Japanese Sporadic Cases of Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis Syndrome from a Single Medical Center in Japan

Erratum

Erratum to: Intact IFN-γR1 Expression and Function Distinguishes Langerhans Cell Histiocytosis From Mendelian Susceptibility to Mycobacterial Disease

Original Research

Reduced BAFF-R and Increased TACI Expression in Common Variable Immunodeficiency

Astute Clinician Report

RAG1 Reversion Mosaicism in a Patient with Omenn Syndrome

Brief Communication

Elevated Double Negative T Cells in Pediatric Autoimmunity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits